TScan Therapeutics (TCRX) Enterprise Value (2020 - 2026)

TScan Therapeutics (TCRX) has 7 years of Enterprise Value data on file, last reported at -$128.1 million in Q1 2026.

• On a quarterly basis, Enterprise Value rose 49.12% year-over-year to -$128.1 million in Q1 2026; TTM through Mar 2026 was -$128.1 million, a 49.12% increase from a year earlier, with the FY2025 full-year figure at -$152.4 million, up 47.47% from the prior year.
• Enterprise Value for Q1 2026 stood at -$128.1 million, up from -$152.4 million in the prior quarter.
• Over the last five years, Enterprise Value for TCRX reached as high as -$95.6 million in Q1 2023 and fell as low as -$297.7 million in Q2 2024.
• Historically, Enterprise Value has averaged -$187.8 million across 5 years, with a median of -$184.5 million in 2025.
• Across the five-year window, Enterprise Value plunged 70.26% in 2024 and surged 49.12% in 2026, its largest moves.
• Year by year, Enterprise Value stood at -$120.0 million in 2022, then plunged by 60.0% to -$192.0 million in 2023, then tumbled by 51.06% to -$290.1 million in 2024, then surged by 47.47% to -$152.4 million in 2025, then climbed by 15.98% to -$128.1 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$128.1 million in Q1 2026, -$152.4 million in Q4 2025, and -$184.5 million in Q3 2025.